aTyr Pharma (NASDAQ:ATYR) Reaches New 12-Month High - Here's What Happened

Key Points

• aTyr Pharma (NASDAQ:ATYR) shares reached a new 52-week high, trading at $7.29, a significant jump from its previous closing price of $5.83.
• Wells Fargo & Company has upgraded its target price for aTyr Pharma from $17.00 to $25.00, while HC Wainwright set a target of $35.00, indicating strong analyst confidence.
• The company's latest earnings report showed that it beat analysts' estimates, reporting a loss of ($0.17) per share against expectations of ($0.19).

aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $7.29 and last traded at $6.84, with a volume of 5557912 shares trading hands. The stock had previously closed at $5.83.

Wall Street Analyst Weigh In

ATYR has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their price objective on aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, June 20th. HC Wainwright restated a "buy" rating and issued a $35.00 price objective on shares of aTyr Pharma in a research note on Wednesday, June 4th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $20.20.

aTyr Pharma Stock Performance

The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $420.08 million, a PE ratio of -5.83 and a beta of 0.89. The company has a 50-day moving average price of $5.19 and a two-hundred day moving average price of $4.04.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. Analysts predict that aTyr Pharma, Inc. will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On aTyr Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Group One Trading LLC bought a new stake in shares of aTyr Pharma during the fourth quarter valued at about $26,000. XTX Topco Ltd increased its position in shares of aTyr Pharma by 74.9% during the first quarter. XTX Topco Ltd now owns 19,556 shares of the company's stock valued at $59,000 after buying an additional 8,374 shares during the period. OMERS ADMINISTRATION Corp boosted its position in shares of aTyr Pharma by 7.3% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 148,100 shares of the company's stock valued at $447,000 after acquiring an additional 10,100 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of aTyr Pharma during the 4th quarter valued at about $39,000. Finally, Two Sigma Advisers LP bought a new stake in shares of aTyr Pharma during the 4th quarter valued at about $44,000. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.